PDCD1 and neoplasm: In the future, we will explore new mechanisms of targeting PD-1 or PD-L1 and new directions in combination therapy, jointly targeting the adaptive stress pathways related to metabolism, oxidation, and DNA damage repair in the tumor, increasing the abundance of tumor immune cells, to provide options for improving response rates and preventing drug resistance.